LFNG Antibody

Code CSB-PA570737
Size US$297
Order now
Image
  • Western blot analysis of extracts from MCF-7 cells and HUVEC cells, using LFNG antibody.
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Full Product Name
Rabbit anti-Homo sapiens (Human) LFNG Polyclonal antibody
Uniprot No.
Target Names
LFNG
Alternative Names
3-N-acetylglucosaminyltransferase lunatic fringe antibody; Beta-1 antibody; Beta-13-N-acetylglucosaminyltransferase lunatic fringe antibody; lfng antibody; LFNG_HUMAN antibody; O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase antibody; SCDO3 antibody
Raised in
Rabbit
Species Reactivity
Human
Immunogen
Synthesized peptide derived from internal of Human LFNG.
Immunogen Species
Homo sapiens (Human)
Clonality
Polyclonal
Purification Method
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Concentration
It differs from different batches. Please contact us to confirm it.
Form
Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Tested Applications
ELISA,WB
Recommended Dilution
Application Recommended Dilution
WB 1:500-1:3000
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Glycosyltransferase that initiates the elongation of O-linked fucose residues attached to EGF-like repeats in the extracellular domain of Notch molecules. Modulates NOTCH1 activity by modifying O-fucose residues at specific EGF-like domains resulting in inhibition of NOTCH1 activation by JAG1 and enhancement of NOTCH1 activation by DLL1 via an increase in its binding to DLL1. Decreases the binding of JAG1 to NOTCH2 but not that of DLL1. Essential mediator of somite segmentation and patterning.
Gene References into Functions
  1. Genetic interaction between lunatic fringe and TP53 was identified in breast cancer tumorigenesis. PMID: 28938159
  2. TGFBR2 signaling can affect Notch1 glycosylation via regulation of glycosyltransferase LFNG expression and provide a first mechanistic example for altered glycosylation in microsatellite instability colorectal tumor cells. PMID: 27156840
  3. LFNG expression correlates with expansion of cancer stem cell populations and NKX3.1 expression in human prostate cancer. PMID: 24709423
  4. Reduced LFNG expression facilitates JAG/NOTCH luminal progenitor signaling and cooperates with MET/CAVEOLIN basal-type signaling to promote basal-like breast cancer. PMID: 22624713
  5. Mutation of the LFNG gene causes spondylocostal dysostosis with a severe vertebral phenotype, reinforcing the hypothesis that proper regulation of the Notch signaling pathway is an absolute requirement for the correct patterning of the axial skeleton. PMID: 16385447

Show More

Hide All

Involvement in disease
Spondylocostal dysostosis 3, autosomal recessive (SCDO3)
Subcellular Location
Golgi apparatus membrane; Single-pass type II membrane protein.
Protein Families
Glycosyltransferase 31 family
Database Links

HGNC: 6560

OMIM: 602576

KEGG: hsa:3955

STRING: 9606.ENSP00000222725

UniGene: Hs.159142

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*